The acceptance of the NDA for Hexvix by the NMPA is a positive regulatory step that could lead to the drug's approval and commercialization in China. This expansion into a new market has the potential to significantly increase Photocure's revenue, as China represents a large market opportunity. The news is directly related to Photocure's business and future prospects, hence the high relevance and importance. The confidence score reflects the positive nature of the regulatory acceptance, although the actual impact on the stock will depend on subsequent approval and commercial success.